Richardson Electronics (RELL) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
8 Jul, 2026Executive summary
Q2 FY25 consolidated net sales rose 12.1% year-over-year to $49.5 million, marking the second consecutive quarterly increase, driven by strong growth in Green Energy Solutions (GES) and Power & Microwave Technology (PMT), partially offset by declines in Healthcare and Canvys.
GES net sales surged 129% year-over-year to $6.0 million, fueled by wind turbine battery modules and new energy storage applications.
Gross margin improved to 31.0% from 28.4% year-over-year, with margin expansion in PMT, GES, and Healthcare.
Operating cash flow was positive for the third straight quarter, with cash and equivalents reaching $26.6 million and no debt.
Net loss for Q2 FY25 narrowed to $0.8 million ($0.05/share), improved from $1.8 million ($0.13/share) in Q2 FY24.
Financial highlights
Q2 FY25 net sales: $49.5 million, up from $44.1 million in Q2 FY24.
Gross margin: 31.0% in Q2 FY25, up from 28.4% in Q2 FY24.
Operating loss reduced to $0.7 million from $2.0 million; net loss narrowed to $0.8 million ($0.05/share) from $1.8 million ($0.13/share) year-over-year.
EBITDA improved to break-even from negative $1.2 million in Q2 FY24.
Cash and equivalents at Q2 end: $26.6 million, up from $23.0 million in Q1.
Outlook and guidance
Management expects higher year-over-year sales and profitability for FY25, supported by sequential backlog growth.
Backlog increased to $142.6 million at Q2 end, up from $137.4 million in Q1 FY25.
GES targets high double-digit revenue growth and 30-40% average gross margin.
PMT expects continued growth in semiconductor wafer fab and RF/microwave components.
Canvys and Healthcare anticipate improved demand in the remainder of FY25.
Latest events from Richardson Electronics
- Q4 net sales up 27.6%, record backlog, and strong outlook with dividend declared.RELL
Q4 202623 Jul 2026 - Q1 FY25 sales up 2.2% to $53.7M, with strong GES and Healthcare growth and a $137.4M backlog.RELL
Q1 20258 Jul 2026 - Q1 FY2026 net income tripled to $1.9M on 1.6% sales growth and improved margins.RELL
Q1 20268 Jul 2026 - Q2 FY26 sales up 5.7% to $52.3M, GES up 39%, backlog $135.7M, $0.06 dividend, no debt.RELL
Q2 202613 Apr 2026 - Q3 FY26 delivered 3.1% sales growth, profitability, and record backlog, led by PMT segment gains.RELL
Q3 202612 Apr 2026 - Sales and profits fell in 2024, but margin, cash flow, and backlog support a positive 2025 outlook.RELL
Q4 20242 Feb 2026 - Q3 net sales up 2.7% YoY, strong PMT/Canvys, $4.9M Healthcare loss, cash $36.7M, no debt.RELL
Q3 202516 Jan 2026 - Shareholders will vote on director elections, auditor ratification, compensation, and capital structure changes.RELL
Proxy Filing1 Dec 2025 - Proxy seeks approval for director elections, auditor, compensation, and share increases.RELL
Proxy Filing1 Dec 2025